Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1820

1.

Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites.

Newton PK, Mason J, Venkatappa N, Jochelson MS, Hurt B, Nieva J, Comen E, Norton L, Kuhn P.

NPJ Breast Cancer. 2015 Oct 21;1:15018. doi: 10.1038/npjbcancer.2015.18. eCollection 2015.

2.

Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System.

Debiasi M, Reinert T, Kaliks R, Amorim G, Caleffi M, Sampaio C, Fernandes GDS, Barrios CH.

J Glob Oncol. 2016 Jul 20;3(3):201-207. doi: 10.1200/JGO.2016.005678. eCollection 2017 Jun.

3.

Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.

Iddawela M, Rueda O, Eremin J, Eremin O, Cowley J, Earl HM, Caldas C.

BMC Genomics. 2017 Jul 11;18(1):526. doi: 10.1186/s12864-017-3867-3.

4.

Chronic Myeloid Leukemia with a Complex Variant 'Ph' Translocation That Develops in Breast Carcinoma, Postchemotherapy: A Rare but Treatable Entity.

Tikku G, Jain M, Shukla P.

J Breast Cancer. 2017 Jun;20(2):208-211. doi: 10.4048/jbc.2017.20.2.208. Epub 2017 Jun 26.

5.

Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review.

Costa R, Costa-Filho RB, Talamantes SM, Queiroga F Jr, Campello EC, Cartaxo H, Costa RB.

Case Rep Oncol. 2017 Jun 14;10(2):524-530. doi: 10.1159/000477340. eCollection 2017 May-Aug.

6.

Molecular genetics complexity impeding research progress in breast and ovarian cancers.

Gupta I, Burney I, Al-Moundhri MS, Tamimi Y.

Mol Clin Oncol. 2017 Jul;7(1):3-14. doi: 10.3892/mco.2017.1275. Epub 2017 May 29.

7.

Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.

Rushton M, Johnson C, Dent S.

Curr Oncol. 2017 Jun;24(3):176-180. doi: 10.3747/co.24.3349. Epub 2017 Jun 27.

8.

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).

Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L.

Int J Mol Med. 2017 Aug;40(2):271-280. doi: 10.3892/ijmm.2017.3036. Epub 2017 Jun 22.

9.

Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.

Yousuf Z, Iman K, Iftikhar N, Mirza MU.

Breast Cancer (Dove Med Press). 2017 Jun 14;9:447-459. doi: 10.2147/BCTT.S132074. eCollection 2017.

10.

Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.

Yoshioka Y, Suzuki T, Matsuo Y, Tsurita G, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R.

Cancer Med. 2017 Jul;6(7):1665-1672. doi: 10.1002/cam4.1099. Epub 2017 Jun 22.

11.

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F.

BMC Cancer. 2017 Jun 19;17(1):425. doi: 10.1186/s12885-017-3420-4.

12.

Precision medicine in breast cancer: reality or utopia?

Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F.

J Transl Med. 2017 Jun 17;15(1):139. doi: 10.1186/s12967-017-1239-z. Review.

13.

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.

Provinciali M, Barucca A, Orlando F, Pierpaoli E.

Sci Rep. 2017 Jun 8;7(1):3078. doi: 10.1038/s41598-017-03286-8.

14.

Cancer cell redirection biomarker discovery using a mutual information approach.

Roche K, Feltus FA, Park JP, Coissieux MM, Chang C, Chan VBS, Bentires-Alj M, Booth BW.

PLoS One. 2017 Jun 8;12(6):e0179265. doi: 10.1371/journal.pone.0179265. eCollection 2017.

15.

Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system.

Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL 3rd, Coleman MA, Henderson PT.

PLoS One. 2017 Jun 6;12(6):e0177761. doi: 10.1371/journal.pone.0177761. eCollection 2017.

16.

The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer.

Shigemizu D, Iwase T, Yoshimoto M, Suzuki Y, Miya F, Boroevich KA, Katagiri T, Zembutsu H, Tsunoda T.

Cancer Med. 2017 Jul;6(7):1627-1638. doi: 10.1002/cam4.1092. Epub 2017 May 24.

17.

Synthesis and Preliminary Biological Evaluations of Fluorescent or 149Promethium Labeled Trastuzumab-Polyethylenimine.

Fitzsimmons J, Nayak T, Cutler C, Atcher R.

Biomedicines. 2015 Dec 30;4(1). pii: E1. doi: 10.3390/biomedicines4010001.

18.

HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer.

Si P, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Oncol Lett. 2017 May;13(5):3793-3798. doi: 10.3892/ol.2017.5866. Epub 2017 Mar 17.

19.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Wee P, Wang Z.

Cancers (Basel). 2017 May 17;9(5). pii: E52. doi: 10.3390/cancers9050052. Review.

20.

Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy.

Yavas G, Celik E, Yavas C, Elsurer C, Afsar RE.

Rep Pract Oncol Radiother. 2017 Jul-Aug;22(4):295-302. doi: 10.1016/j.rpor.2017.01.004. Epub 2017 May 5.

PMID:
28507459

Supplemental Content

Support Center